1. Home
  2. PSQH vs IMMP Comparison

PSQH vs IMMP Comparison

Compare PSQH & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PSQ Holdings Inc.

PSQH

PSQ Holdings Inc.

HOLD

Current Price

$3.39

Market Cap

29.3M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

SELL

Current Price

$3.26

Market Cap

31.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PSQH
IMMP
Founded
2021
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.3M
31.5M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
PSQH
IMMP
Price
$3.39
$3.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.6K
★ 144.1K
Earning Date
11-05-2026
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.00
N/A
EPS
N/A
★ N/A
Revenue
★ $5,685,987.00
N/A
Revenue This Year
$81.45
N/A
Revenue Next Year
$35.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1096.61
N/A
52 Week Low
$0.36
$0.26
52 Week High
$6.94
$5.36

Technical Indicators

Market Signals
Indicator
PSQH
IMMP
Relative Strength Index (RSI) 30.66 60.14
Support Level $0.51 $2.65
Resistance Level $5.73 $5.36
Average True Range (ATR) 0.35 0.23
MACD -0.12 -0.15
Stochastic Oscillator 5.61 9.94

Price Performance

Historical Comparison
PSQH
IMMP

About PSQH PSQ Holdings Inc.

PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: